This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Merus Förvaltning

Förvaltning kriterier kontrolleras 1/4

Vi har för närvarande inte tillräcklig information om VD:n.

Viktig information

Jan van de Winkel

Verkställande direktör

n/a

Total ersättning

VD-lön i procent	n/a
Anställning som VD	no data
Ägande av VD	n/a
Ledningens genomsnittliga anställningstid	3.2yrs
Styrelsens genomsnittliga mandatperiod	inga uppgifter

Senaste uppdateringar av ledningen

Recent updates

Genmab Buys Merus For $8bn: A Good Deal If Potential Is Converted Into Revenue

Sep 29

Need To Know: The Consensus Just Cut Its Merus N.V. (NASDAQ:MRUS) Estimates For 2025

Mar 05

Earnings Update: Merus N.V. (NASDAQ:MRUS) Just Reported Its Full-Year Results And Analysts Are Updating Their Forecasts

Mar 02

Merus N.V.'s Innovative Cancer Therapies: Balancing Its IP Potential With Financial Risks

Aug 14

Merus Stock: Priced High After An ASCO Surprise Surge (Maintain Buy)

May 24

Merus: Positive Zenocutuzumab Data In 2024 Could Provide BLA Advancement

Mar 01

Merus Stock: Rally Seems Overdone

Jan 23

Merus GAAP EPS of -$0.13 beats by $0.49, revenue of $12.68M beats by $2.23M

Aug 08

Merus N.V. initiated with Buy at Stifel based on three bispecific antibodies

Aug 02

Merus: Precision Oncology Pioneer Continues To Execute In The Clinic

Jun 30

VD OCH KONCERNCHEF

Jan van de Winkel

no data

Anställning

Dr. Jan G.J. van de Winkel, Ph D., is CEO & Executive Director of Merus N.V. from December 11, 2025. Dr. van de Winkel is a co-founder of Genmab and served as President, Research & Development and Chief Sc...

Ledningsgrupp

Namn	Position	Anställning	Kompensation	Ägarskap
Gregory Perry	Chief Financial Officer	2.5yrs	US$3.26m	0% $ 0
Peter Silverman	EVP, Company Secretary	7.8yrs	US$3.40m	0% $ 0
Fabian Zohren	Chief Medical Officer	1.4yrs	US$7.20m	0% $ 0
Jan van de Winkel	CEO & Executive Director	no data	inga uppgifter	inga uppgifter
Hennie Hoogenboom	Co-Founder and Scientific Advisor	no data	inga uppgifter	inga uppgifter
Harry Shuman	Chief Accounting Officer	no data	inga uppgifter	0% $ 0
Cornelis de Kruif	CTO & Executive VP	12.9yrs	US$609.22k	inga uppgifter
Cecilia Anna Geuijen	Chief Scientific Officer & Senior VP	4.6yrs	inga uppgifter	inga uppgifter
Sherri Spear	Senior Vice President of Investor Relations & Strategic Communications	no data	inga uppgifter	inga uppgifter
Kathleen Farren	Director of IR & Corporate Communications Officer	no data	inga uppgifter	inga uppgifter
Audrey Bergan	Chief People Officer	1.1yrs	inga uppgifter	inga uppgifter
Shannon Campbell	Executive VP & Chief Commercial Officer	3.8yrs	inga uppgifter	inga uppgifter

3.2yrs

Genomsnittlig anställningstid

59yo

Genomsnittlig ålder

Erfaren ledning: MRUS s ledningsgrupp anses vara erfaren ( 3.2 års genomsnittlig anställningstid).

Företagsanalys och finansiella data Status

Uppgifter	Senast uppdaterad (UTC-tid)
Analys av företag	2025/12/31 03:09
Aktiekurs vid dagens slut	2025/12/29 00:00
Intäkter	2025/09/30
Årlig intjäning	2024/12/31

Datakällor

Den data som används i vår företagsanalys kommer från S&P Global Market Intelligence LLC. Följande data används i vår analysmodell för att generera denna rapport. Data är normaliserade vilket kan medföra en fördröjning från det att källan är tillgänglig.

Paket	Uppgifter	Tidsram	Exempel US-källa
Företagets finansiella ställning	10 år	Resultaträkning Kassaflödesanalys Balansräkning	SEC Form 10-K SEC Form 10-Q
Analytikernas konsensusuppskattningar	+3 år	Prognos för finansiella poster Analytikernas prismål	Rapporter från analytiker Blue Matrix
Marknadspriser	30 år	Aktiekurser Utdelningar, splittar och åtgärder	ICE Marknadsdata SEC Form S-1
Ägarskap	10 år	Största aktieägare Insiderhandel	SEC Formulär 4 SEC Formulär 13D
Förvaltning	10 år	Ledningsgrupp Styrelse och verkställande direktörer	SEC Form 10-K SEC Form DEF 14A
Viktiga utvecklingstendenser	10 år	Företagsmeddelanden	SEC Formulär 8-K

^* Exempel för amerikanska värdepapper, för icke-amerikanska värdepapper används motsvarande regelverk och källor.

Om inget annat anges är all finansiell data baserad på en årsperiod men uppdateras kvartalsvis. Detta kallas data för efterföljande tolv månader (TTM) eller senaste tolv månader (LTM). Lär dig mer om detta.

Analysmodell och snöflinga

Detaljer om den analysmodell som används för att generera denna rapport finns på vår Github-sida, vi har också guider om hur man använder våra rapporter och tutorials på Youtube.

Lär dig mer om det team i världsklass som utformade och byggde analysmodellen Simply Wall St.

Industri- och sektormått

Våra bransch- och sektionsmått beräknas var sjätte timme av Simply Wall St, detaljer om vår process finns tillgängliga på Github.

Källor för analytiker

Merus N.V. bevakas av 24 analytiker. 15 av dessa analytiker lämnade de uppskattningar av intäkter eller resultat som användes som indata till vår rapport. Analytikernas inskickade estimat uppdateras löpande under dagen.

Analytiker	Institution
Matthew Venezia	Alliance Global Partners
Etzer Darout	Barclays
Etzer Darout	BMO Capital Markets Equity Research

This company has been acquired

Merus Förvaltning

Förvaltning kriterier kontrolleras 1/4

Viktig information

Senaste uppdateringar av ledningen

Merus N.V., Annual General Meeting, May 21, 2025

Merus N.V. Announces Chief Medical Officer Changes

Merus N.V. Appoints Jason Haddock as Non-Executive Director

Merus N.V., Annual General Meeting, May 07, 2024

EVP, Company Secretary notifies of intention to sell stock

Merus Appoints Greg Perry as Chief Financial Officer

Recent updates

Merus N.V.(NasdaqGM:MRUS) dropped from NASDAQ Composite Index

Merus to Delist All Common Shares from Nasdaq

Merus N.V.(NasdaqGM:MRUS) dropped from NASDAQ Biotechnology Index

Genmab A/S (CPSE:GMAB) completed the acquisition of Merus N.V. (NasdaqGM:MRUS) in a tender offer transaction.

Genmab Buys Merus For $8bn: A Good Deal If Potential Is Converted Into Revenue

Genmab Reportedly in Advanced Talks to Buy Merus

Merus N.V. has completed a Follow-on Equity Offering in the amount of $300.000006 million.

Merus, N.V. Provides Updates on Clinical Development

Merus N.V. Announces Interim Data Demonstrates Robust Efficacy and Durability in 1L Pembrolizumab

Merus N.V., Annual General Meeting, May 21, 2025

Need To Know: The Consensus Just Cut Its Merus N.V. (NASDAQ:MRUS) Estimates For 2025

Earnings Update: Merus N.V. (NASDAQ:MRUS) Just Reported Its Full-Year Results And Analysts Are Updating Their Forecasts

Here's Why We're Not Too Worried About Merus' (NASDAQ:MRUS) Cash Burn Situation

Time To Upgrade Merus N.V. To A 'Buy' After The Recent Selloff

Merus N.V. Announces That the United States Food and Drug Administration Approves Bizengri (Zizengri) for Treatment Indicated for Adults with Pancreatic Adenocarcinoma or Non Small Cell Lung Cancer

Merus: Petosemtamab Set Up For December 2024 Data Presentation

Merus N.V. Announces First Patient Dosed in Liger-Hn1, A Phase 3 Trial Evaluating Petosemtamab in Combination with Pembrolizumab in 1L R/M HNSCC

Merus N.V.'s Innovative Cancer Therapies: Balancing Its IP Potential With Financial Risks

Merus N.V. Announces First Patient Dosed in Phase 2 Trial of Petosemtamab in 2L CRC

Merus N.V. Announces Chief Medical Officer Changes

Merus N.V. Presents Interim Data on MCLA-145 Monotherapy and in Combination with Pembrolizumab At the 2024 ASCO® Annual Meeting

Merus N.V. has completed a Follow-on Equity Offering in the amount of $400.15 million.

Merus N.V. has filed a Follow-on Equity Offering in the amount of $300 million.

Price target increased by 21% to US$73.36

Merus Stock: Priced High After An ASCO Surprise Surge (Maintain Buy)

Consensus revenue estimates increase by 26%

Merus N.V. Announces Petosemtamab Grants Breakthrough Therapy Designation by the U.S. FDA

First quarter 2024 earnings released: US$0.59 loss per share (vs US$0.86 loss in 1Q 2023)

Merus N.V. Appoints Jason Haddock as Non-Executive Director

Merus N.V., Annual General Meeting, May 07, 2024

Price target increased by 7.6% to US$59.18

Merus N.V. announced that it has received $25.000035 million in funding from Gilead Sciences, Inc.

Full year 2023 earnings: EPS and revenues miss analyst expectations

Merus: Positive Zenocutuzumab Data In 2024 Could Provide BLA Advancement

Price target increased by 16% to US$51.60

Merus N.V. has filed a Follow-on Equity Offering in the amount of $300 million.

Merus Stock: Rally Seems Overdone

EVP, Company Secretary notifies of intention to sell stock

Consensus EPS estimates upgraded to US$2.60 loss

Consensus estimates of losses per share improve by 12%

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Merus N.V. Announces Interim Data Continues to Demonstrate Robust and Durable Responses in NRG1+ Cancer

New major risk - Revenue and earnings growth

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

U.S. Food and Drug Administration Grants Second Breakthrough Therapy Designation for zenocutuzumab (Zeno) of Merus N.V

Merus Appoints Greg Perry as Chief Financial Officer

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Consensus EPS estimates upgraded to US$3.63 loss

Independent Non Executive Director exercised options to buy US$1.5m worth of stock.

Price target increased by 8.6% to US$40.67

Price target increased by 8.5% to US$39.67

Chief Business Officer exercised options to buy US$1.9m worth of stock.

Full year 2022 earnings released: US$2.92 loss per share (vs US$1.73 loss in FY 2021)

Now 21% undervalued

Merus N.V. Announces Executive Changes

Price target decreased to US$37.11

Consensus forecasts updated

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Price target decreased to US$38.44

Consensus forecasts updated

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Merus GAAP EPS of -$0.13 beats by $0.49, revenue of $12.68M beats by $2.23M

Merus N.V. initiated with Buy at Stifel based on three bispecific antibodies

Merus: Precision Oncology Pioneer Continues To Execute In The Clinic

Consensus revenue estimates increase by 15%

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

Executive VP exercised options and sold US$947k worth of stock

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind